[CLSTR]
< Back to situations

Monitor this situation.

[SITUATION] · [ACTIVE] · [HEALTH]

4 clusters · 11 sources · 5 days · First seen · Last updated

Advancements in AI-driven cancer blood tests

Overview

Recent developments in oncology highlight advancements in liquid biopsy technology for early cancer detection using artificial intelligence and machine learning. An international research team led by City of Hope developed the PANXEON blood test, which utilizes AI to analyze microRNA and the protein CA19-9. In clinical testing, this method correctly identified 87% of pancreatic cancers at stages 1 and 2, while maintaining a low false-positive rate. Channing Der, a professor at the University of North Carolina at Chapel Hill, noted that the results are “very impressive and promising,” stating that the test far exceeds the limitations of the current gold standard, the CA19-9 blood marker. Concurrently, the PATHFINDER 2 study demonstrated the efficacy of the Galleri blood test. This test analyzes circulating DNA fragments to detect over 50 cancer types, including pancreatic, ovarian, and liver cancers. The study, involving 32,007 participants, found that nearly half of new detections occurred in stages one or two, and nearly three-quarters occurred in stages one through three. The test achieved a specificity of 99.64% and a positive predictive value of 60.3%, while correctly predicting the likely location of the cancer in 91.3% of cases. New research suggests these tests may identify cancer years before clinical diagnosis. A study involving the Pathlight blood test at Lund University found that circulating tumor DNA could identify metastatic breast cancer a median of 13.8 months before it was clinically visible, with some signals appearing nearly four years in advance. Additionally, a longitudinal study published in Cell Genomics involving researchers from the University of Toronto, the Ontario Institute for Cancer Research, and the University of Oxford found that epigenetic alterations and cell-free DNA signatures could appear in blood plasma up to eight years before diagnosis.

Entities

Nature Medicine · University of Oxford · University of North Carolina at Chapel Hill · American Cancer Society · University of Toronto

Timeline

  1. 1 day ago

    [HEALTH] 3 sources
    New blood test detects pancreatic cancer with 87% accuracy

    A new blood test combining three biological markers can detect pancreatic cancer in early stages with 87% accuracy, potentially surpassing current diagnostic standards.

  2. 1 day ago

    [HEALTH] 3 sources
    Blood tests show potential to detect cancer years before clinical diagnosis

    Studies show blood tests can detect molecular signs of breast and prostate cancer years before traditional scans identify tumors, potentially transforming early cancer monitoring.

  3. 3 days ago

    [HEALTH] 3 sources
    Galleri blood test detects over 50 cancer types in early stages

    The PATHFINDER 2 study shows the Galleri AI blood test can detect over 50 types of cancer, including pancreatic and ovarian, often in early stages with high specificity.

  4. 5 days ago

    [HEALTH] 3 sources
    City of Hope leads development of early-stage pancreatic cancer blood test

    A new AI-driven blood test led by City of Hope can detect 87% of early-stage pancreatic cancers and identify precancerous changes, offering hope for earlier diagnosis and treatment.

Sources

bild.de · fehmarn24.de · healthreport.gr · hna.de · knowridge.com · ortho-online.de · pelop.gr · politis.com.cy · thebrighterside.news · trendsderzukunft.de · world-today-news.com

This summary has been updated 2 times: see revision history